86 related articles for article (PubMed ID: 17321670)
21. Arsenic exposure disrupts the normal function of the FA/BRCA repair pathway.
Peremartí J; Ramos F; Marcos R; Hernández A
Toxicol Sci; 2014 Nov; 142(1):93-104. PubMed ID: 25092648
[TBL] [Abstract][Full Text] [Related]
22. Functional screen of the fanconi anemia pathway in cancer cells by Fancd2 immunoblot.
Van Der Heijden MS; Brody JR; Kern SE
Cancer Biol Ther; 2004 Jun; 3(6):534-7. PubMed ID: 15107617
[TBL] [Abstract][Full Text] [Related]
23. Chemosensitizing tumor cells by targeting the Fanconi anemia pathway with an adenovirus overexpressing dominant-negative FANCA.
Ferrer M; de Winter JP; Mastenbroek DC; Curiel DT; Gerritsen WR; Giaccone G; Kruyt FA
Cancer Gene Ther; 2004 Aug; 11(8):539-46. PubMed ID: 15192709
[TBL] [Abstract][Full Text] [Related]
24. SERPINB2 down-regulation contributes to chemoresistance in head and neck cancer.
Huang Z; Li H; Huang Q; Chen D; Han J; Wang L; Pan C; Chen W; House MG; Nephew KP; Guo Z
Mol Carcinog; 2014 Oct; 53(10):777-86. PubMed ID: 23661500
[TBL] [Abstract][Full Text] [Related]
25. Glutathione S-transferase pi amplification is associated with cisplatin resistance in head and neck squamous cell carcinoma cell lines and primary tumors.
Cullen KJ; Newkirk KA; Schumaker LM; Aldosari N; Rone JD; Haddad BR
Cancer Res; 2003 Dec; 63(23):8097-102. PubMed ID: 14678959
[TBL] [Abstract][Full Text] [Related]
26. Analysis of a FANCE Splice Isoform in Regard to DNA Repair.
Bouffard F; Plourde K; Bélanger S; Ouellette G; Labrie Y; Durocher F
J Mol Biol; 2015 Sep; 427(19):3056-73. PubMed ID: 26277624
[TBL] [Abstract][Full Text] [Related]
27. The BRCA1-interacting helicase BRIP1 is deficient in Fanconi anemia.
Levran O; Attwooll C; Henry RT; Milton KL; Neveling K; Rio P; Batish SD; Kalb R; Velleuer E; Barral S; Ott J; Petrini J; Schindler D; Hanenberg H; Auerbach AD
Nat Genet; 2005 Sep; 37(9):931-3. PubMed ID: 16116424
[TBL] [Abstract][Full Text] [Related]
28. BRCA/Fanconi anemia pathway implicates chemoresistance to gemcitabine in biliary tract cancer.
Nakashima S; Kobayashi S; Nagano H; Tomokuni A; Tomimaru Y; Asaoka T; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Doki Y; Mori M
Cancer Sci; 2015 May; 106(5):584-91. PubMed ID: 25736055
[TBL] [Abstract][Full Text] [Related]
29. Fanconi anemia D2 protein confers chemoresistance in response to the anticancer agent, irofulven.
Wang Y; Wiltshire T; Senft J; Wenger SL; Reed E; Wang W
Mol Cancer Ther; 2006 Dec; 5(12):3153-61. PubMed ID: 17172419
[TBL] [Abstract][Full Text] [Related]
30. FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.
Wilson JB; Yamamoto K; Marriott AS; Hussain S; Sung P; Hoatlin ME; Mathew CG; Takata M; Thompson LH; Kupfer GM; Jones NJ
Oncogene; 2008 Jun; 27(26):3641-52. PubMed ID: 18212739
[TBL] [Abstract][Full Text] [Related]
31. Involvement of Fanconi anemia genes FANCD2 and FANCF in the molecular basis of drug resistance in leukemia.
Yao C; Du W; Chen H; Xiao S; Huang L; Chen FP
Mol Med Rep; 2015 Jun; 11(6):4605-10. PubMed ID: 25647473
[TBL] [Abstract][Full Text] [Related]
32. Biomarkers and mechanisms of FANCD2 function.
Willers H; Kachnic LA; Luo CM; Li L; Purschke M; Borgmann K; Held KD; Powell SN
J Biomed Biotechnol; 2008; 2008():821529. PubMed ID: 18483568
[TBL] [Abstract][Full Text] [Related]
33. Fanconi anemia D2 protein is an apoptotic target mediated by caspases.
Park SJ; Beck BD; Saadatzadeh MR; Haneline LS; Clapp DW; Lee SH
J Cell Biochem; 2011 Sep; 112(9):2383-91. PubMed ID: 21520247
[TBL] [Abstract][Full Text] [Related]
34. Genetic and expression profiles of squamous cell carcinoma of the head and neck correlate with cisplatin sensitivity and resistance in cell lines and patients.
Akervall J; Guo X; Qian CN; Schoumans J; Leeser B; Kort E; Cole A; Resau J; Bradford C; Carey T; Wennerberg J; Anderson H; Tennvall J; Teh BT
Clin Cancer Res; 2004 Dec; 10(24):8204-13. PubMed ID: 15623595
[TBL] [Abstract][Full Text] [Related]
35. Chemosensitization to cisplatin by inhibitors of the Fanconi anemia/BRCA pathway.
Chirnomas D; Taniguchi T; de la Vega M; Vaidya AP; Vasserman M; Hartman AR; Kennedy R; Foster R; Mahoney J; Seiden MV; D'Andrea AD
Mol Cancer Ther; 2006 Apr; 5(4):952-61. PubMed ID: 16648566
[TBL] [Abstract][Full Text] [Related]
36. The Fanconi Anemia/BRCA signaling pathway: disruption in cisplatin-sensitive ovarian cancers.
D'Andrea AD
Cell Cycle; 2003; 2(4):290-2. PubMed ID: 12851475
[TBL] [Abstract][Full Text] [Related]
37. CD24 Expression May Play a Role as a Predictive Indicator and a Modulator of Cisplatin Treatment Response in Head and Neck Squamous Cellular Carcinoma.
Modur V; Joshi P; Nie D; Robbins KT; Khan AU; Rao K
PLoS One; 2016; 11(6):e0156651. PubMed ID: 27276062
[TBL] [Abstract][Full Text] [Related]
38. Altered expression of FANCL confers mitomycin C sensitivity in Calu-6 lung cancer cells.
Zhang J; Wang X; Lin CJ; Couch FJ; Fei P
Cancer Biol Ther; 2006 Dec; 5(12):1632-6. PubMed ID: 17106252
[TBL] [Abstract][Full Text] [Related]
39. Alcohol metabolism in human cells causes DNA damage and activates the Fanconi anemia-breast cancer susceptibility (FA-BRCA) DNA damage response network.
Abraham J; Balbo S; Crabb D; Brooks PJ
Alcohol Clin Exp Res; 2011 Dec; 35(12):2113-20. PubMed ID: 21919919
[TBL] [Abstract][Full Text] [Related]
40. Inhibition of USP28 overcomes Cisplatin-resistance of squamous tumors by suppression of the Fanconi anemia pathway.
Prieto-Garcia C; Hartmann O; Reissland M; Fischer T; Maier CR; Rosenfeldt M; Schülein-Völk C; Klann K; Kalb R; Dikic I; Münch C; Diefenbacher ME
Cell Death Differ; 2022 Mar; 29(3):568-584. PubMed ID: 34611298
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
